Prevention of Complications (SARS-CoV-2): Clinical Study
Status:
Completed
Trial end date:
2020-12-23
Target enrollment:
Participant gender:
Summary
Viral diseases have always posed a threat to public health. Recently, the SARS-Cov2 virus
spread in an epidemic that began in China and soon spread globally, making its study
extremely relevant, in order to seek mechanisms to combat it. Therefore, this study seeks to
evaluate the benefit of using Hydroxychloroquine with or without Apixaban in the early
treatment of patients with suspected COVID-19. Prospective, randomized, double-blind,
controlled study, performed at Hospital das Clínicas Samuel Libânio (Universidade do Vale do
Sapucaí) UNIVÁS, Pouso Alegre, Minas Gerais, Brasil. Patients treated in the emergency
department who are reported as suspected cases of COVID-19 patients will be included,
according to current guidelines. Will be randomized into 4 groups: Hydroxychloroquine,
Hydroxychloroquine + Apixabana, only Apixabana and Control group, all receiving standard
treatment recommended. Included patients will be monitored during hospitalization or remotely
assisted in home treatment. Clinical, laboratory, electrocardiographic and image evaluation
criteria will be considered to assess the evolution in 7 and 14 days after inclusion. Results
will be subjected to appropriate statistical analysis, with sample calculation. An early
therapeutic approach is proposed in suspected and confirmed patients with COVID-19, with the
hope of reducing hospitalizations and severe forms of the disease.